These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 12679396)

  • 1. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
    Buchmann I; Vogg AT; Glatting G; Schultheiss S; Möller P; Leithäuser F; Schulte M; Gfrörer W; Kotzerke J; Reske SN
    Cancer Biother Radiopharm; 2003 Jun; 18(3):327-37. PubMed ID: 12954120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
    Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
    J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
    Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
    J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
    Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
    Larson SM; Morris M; Gunther I; Beattie B; Humm JL; Akhurst TA; Finn RD; Erdi Y; Pentlow K; Dyke J; Squire O; Bornmann W; McCarthy T; Welch M; Scher H
    J Nucl Med; 2004 Mar; 45(3):366-73. PubMed ID: 15001675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
    Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
    J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
    Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
    J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the normal adrenal gland with 18F-FDG PET/CT.
    Bagheri B; Maurer AH; Cone L; Doss M; Adler L
    J Nucl Med; 2004 Aug; 45(8):1340-3. PubMed ID: 15299059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
    Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
    J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
    Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH
    J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
    Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
    J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
    Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
    J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
    Dimitrakopoulou-Strauss A; Strauss L
    Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
    Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
    J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in peripheral tumors: first clinical results.
    Pauleit D; Stoffels G; Schaden W; Hamacher K; Bauer D; Tellmann L; Herzog H; Bröer S; Coenen HH; Langen KJ
    J Nucl Med; 2005 Mar; 46(3):411-6. PubMed ID: 15750152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
    Beaulieu S; Kinahan P; Tseng J; Dunnwald LK; Schubert EK; Pham P; Lewellen B; Mankoff DA
    J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
    Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
    Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.